Timing of Drotrecogin Alfa Treatment in Severe Sepsis
Author Information
Author(s): Vincent Jean-Louis, O'Brien James Jr, Wheeler Arthur, Wittebole Xavier, Garg Rekha, Trzaskoma Benjamin L, Sundin David P
Primary Institution: Erasme Hospital, Free University of Brussels
Hypothesis
Does earlier treatment with drotrecogin alfa (activated) improve outcomes in patients with severe sepsis?
Conclusion
Earlier treatment with drotrecogin alfa is associated with lower risk-adjusted mortality compared to later treatment.
Supporting Evidence
- Increased time-to-treatment with drotrecogin alfa was linked to more organ dysfunction.
- Patients treated within 24 hours had a higher survival rate at 28 days compared to those treated later.
- The study analyzed data from five clinical trials to assess treatment timing.
Takeaway
Giving a medicine called drotrecogin alfa sooner to very sick patients can help them live longer.
Methodology
Data from 4,459 patients in five clinical trials were analyzed to evaluate the timing of drotrecogin alfa treatment and its effects on survival.
Potential Biases
Potential bias from differences in the natural progression of severe sepsis and the non-randomized nature of the data.
Limitations
The study was not a single randomized trial, and adjustments were limited to measured covariates.
Participant Demographics
Patients included were from various countries, with a mix of demographics including age and sex.
Statistical Information
P-Value
0.03
Statistical Significance
p = 0.03
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website